Regulatory updates, product alerts, peer-reviewed research highlights, and HSI announcements — filtered by region. Editorial commentary, not promotional.
Why "masseter Botox" is trending — HSI practice-intelligence analysis
Semrush UK data puts "masseter botox" at 18,100 searches a month, with a wider cluster of roughly 32,800 including "botox for teeth grinding" and "jaw slimming botox". HSI analyses the six converging drivers — the FDA acceptance of Allergan's sBLA for masseter muscle prominence, dual aesthetic and bruxism intent, the social-media backlash loop, GLP-1-related facial volume loss, facial balancing and male demand, and the clinic content flywheel — and sets out what each means for consultation, compliant advertising and technique.
New CQC-registered medical cannabis clinic opens as UK private market passes 140,000 patients
A new Care Quality Commission-registered medical cannabis clinic, Medecan, has launched in the UK, co-founded by NHS GP and chief medical officer Dr David Eccleston, offering a regulated prescribing pathway for chronic pain, cancer, inflammatory and neurological disorders, PTSD, anxiety and sleep disorders. The opening comes as Prohibition Partners estimates the UK medical cannabis market at £302–389 million with more than 140,000 patients in 2026. Harley Street Institute has published a business-facing review of what it costs to set up a compliant clinic, how pricing works, and the pros and cons for clinicians considering entry.
DHSC consults on six new safeguards for commercial sunbeds in England
The Department of Health and Social Care opened a consultation on 22 May 2026 (closed 14 August 2026) proposing mandatory photo-ID age verification, staff supervision, a ban on selling or hiring sunbed devices to under-18s, mandatory pre-sale health risk information, certified protective eyewear, and a prohibition on promoting unproven health benefits. An outright commercial ban was not consulted on, despite the British Photodermatology Group and British Association of Dermatologists calling for one. Harley Street Institute has published a four-lens review of the health, economic and psychological evidence.
MHRA strengthens iatrogenic botulism warnings for all botulinum toxin type A products
The Medicines and Healthcare products Regulatory Agency has updated product information and patient leaflets across all botulinum toxin type A products following rare reports of iatrogenic botulism, where toxin effect extends beyond the treated area. Symptoms — difficulty swallowing, slurred speech, breathing difficulty and generalised weakness — typically appear within four to eight days but may take up to four weeks. Harley Street Institute has published a commentary arguing that reported cosmetic dysphagia is concentrated in platysma treatment and reflects dose, depth and technique rather than unpredictable spread.
Aesthetic Intelligence — Volume 1, Issue 6 now online
Issue 6 leads with a critical evidence review of the therapeutic peptide landscape, alongside articles on necrosis management, dermal filler complications, and migraine prevention with botulinum toxin.
The Harley Street Institute’s open-access journal Aesthetic Intelligence has been formally registered with ISSN 2979-8116, supporting long-term indexing, citation, and archival permanence.
MHRA reiterates position on unlicensed therapeutic peptides
The Medicines and Healthcare products Regulatory Agency has reissued guidance clarifying that BPC-157, TB-500, and similar research peptides remain unlicensed for human use in the UK, with medicinal claims constituting an offence under the Human Medicines Regulations 2012.
JCCP welcomes Department of Health licensing scheme progress
The Joint Council for Cosmetic Practitioners reports that secondary legislation under Section 180 of the Health and Care Act 2022 is progressing, moving toward statutory licensing for non-surgical cosmetic procedures in England.
GMC updates CPD expectations for doctors practising aesthetic medicine
The General Medical Council has issued supplementary guidance reinforcing that doctors practising in cosmetic interventions are expected to evidence CPD relevant to their scope of practice — a domain in which structured AiCE-aligned activity contributes.
MHRA approves stronger dosage of semaglutide for weight management
The Medicines and Healthcare products Regulatory Agency has approved a new maximum weekly dose of semaglutide up to 7.2mg for adults with obesity (BMI ≥30 kg/m²). The higher dose is administered as three consecutive 2.4mg injections following a structured escalation schedule, and does not apply to cardiovascular-risk indications.
Industry news is curated by the HSI editorial board. Items summarise external regulatory, product, and peer-reviewed developments and link to primary sources. They do not constitute clinical guidance. For peer-reviewed analysis, see the main journal.